Mysterious Two-Mile Wide Dome Slithers in Pacific Ocean
Wanna see for yourself? Check it out at 49°50'43.0'N 140°13'21.0'W.
Conspiracy theorists and obsessively online individuals have jumped on the case, exposing the mystery, speculating wildly as to what it might be (aliens! Godzilla!), and following its movements.
One commenter, however, took a different track than the tin foil hat community. Instead, they offered a more plausible explanation:
'You're not looking at a crawling dome. You're looking at a low-res sonar stitch glitch on Google Earth's bathymetric layer. What you're calling a 2-mile sea creature is just cartographic noise from overlapping survey lines and interpolation gaps.'This is what happens when someone opens Google Earth, sees a shadow, and decides they're Deep Sea Dora the Explorer with zero understanding of how seafloor mapping works. These aren't alien trails. They're digital potholes from outdated sonar passes.'Recently, a similar situation involving a strange object observed on Google Earth underwater caused a stir. That time, the perceived anomaly was off the coast of Malibu. It showed Sycamore Knoll, a submerged topographical feature, which conspiracy theorists ventured that it could be a covert military base or, of course, aliens. Then, adding to the mystery, it disappeared from Google.
As for this new anomaly stoking speculation, there's been no certifiable explanation yet. Is it a glitch in Google Earth's mapping technology? Or something more sci-fi? Commence speculation. Mysterious Two-Mile Wide Dome Slithers in Pacific Ocean first appeared on Surfer on Jun 16, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Learn About: NASA's Lucy Spacecraft Flyby With Asteroid Donaldjohanson
Learn more about the Lucy mission "fly past 52246 Donaldjohanson -NASA's Goddard Space Flight Center. Credit: NASA's Goddard Space Flight Center Dan Gallagher: Producer/Narrator Adriana Manrique Gutierrez: Animator Kel Elkins: Animator Johathan North: Animator Michael Lentz: Animator/Art Director Walt Feimer: Animation Lead Nancy Jones: Public Affairs Katherine Kretke: Public Affairs Universal Production Music: 'Nico's Journey' by Nicholas Smith [PRS]; 'Knowing Half the Future' and 'Temporal Timings' by Lee John Gretton [PRS]; 'Poly Propulsion' by Alfie Solo [PRS]
Yahoo
39 minutes ago
- Yahoo
Thermo Fisher's NGS Assay Receives FDA Approval as a Companion Diagnostic for ZEGFROVY and for Tumor Profiling
Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer generates results in as little as 24 hours to support timely therapy decisions CARLSBAD, Calif., July 03, 2025--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the U.S. Food and Drug Administration (FDA) has approved the Oncomine™ Dx Express Test on the Ion Torrent™ Genexus™ Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay for use as a companion diagnostic (CDx) for Dizal's ZEGFROVY® (sunvozertinib) and in tumor profiling. This approval brings rapid next-generation sequencing (NGS) to decentralized clinical settings closer to where patients receive care. With the ability to deliver essential genomic insights in as little as 24 hours*, this approval helps advance the accessibility of precision oncology tools and enables more timely decision making. A patient's tumor profile has the potential to guide precision oncology care. However, delays in obtaining results can hinder clinicians' ability to make informed decisions, potentially causing patients to miss out on targeted therapies, which can impact treatment efficacy and patient outcomes. Furthermore, a significant number of patients miss out on targeted therapies due to inefficiencies or lack of access to testing, highlighting the critical role of timely genomic profiling. The Oncomine Dx Express Test was designed to simplify the NGS workflow and connect patients everywhere to precision oncology. Now with the Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer, laboratories across a variety of clinical settings can deliver rapid genomic profiling with exceptional accuracy and ease, helping to ensure patients can benefit from the latest advancements in precision oncology. The Oncomine Dx Express Test is intended for use as a companion diagnostic for ZEGFROVY (sunvozertinib), a targeted therapy from Dizal, to identify patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. In addition, the test has been approved for tumor profiling in solid tumors and detects cancer mutations with evidence of clinical significance and potential clinical significance across 46 genes. Accelerating informed precision oncology care The Genexus Dx Integrated Sequencer automates the NGS workflow — from sample preparation to data analysis and reporting — making the technology accessible to more laboratories, including those that are smaller and without previous NGS expertise. It also enables laboratories to generate timely CDx results as well as tumor profiling reports in as little as 24 hours, helping accelerate insights and access to precision oncology. "NGS has been instrumental in advancing precision oncology, but these insights often aren't available early enough to inform real-world care," said Kathy Davy, president of Clinical Next-Generation Sequencing at Thermo Fisher Scientific. "With our rapid NGS solutions, we aim to deliver timely results to clinicians and their patients prior to the initiation of treatment. We've been leading companion diagnostics in collaboration with our pharma partners for a decade, and this approval signifies the next step in our journey bringing rapid, decentralized NGS CDx to drug development. We are proud of our collaboration with Dizal to bring ZEGFROVY to the US market." Biodesix, one of Thermo Fisher's collaborators in the validation of Oncomine Dx Express Test on the Genexus Dx Integrated Sequencer, will be the first lab to launch testing services. "The Biodesix team is excited at the prospect of using the newly FDA approved Genexus Dx Integrated Sequencer for clinical testing using the Oncomine Dx Express test and for supporting our biopharma client projects," said Gary Pestano, Ph.D., chief development officer at Biodesix. "Automation of the systems for nucleic acid purification, library preparation, sequencing and report generation has the potential to significantly improve our NGS laboratory workflows by reducing hands-on time and by delivering rapid turnaround times - from sample receipt to results." ZEGFROVY (sunvozertinib) CDx approval ZEGFROVY, developed by Dizal, was granted FDA accelerated approval following Breakthrough Therapy designation and Priority Review for the treatment of NSCLC patients with EGFR exon 20 insertion mutations. With the approval of the Oncomine Dx Express Test on the Genexus Dx Integrated Sequencer as a companion diagnostic for this therapy, clinicians can now quickly identify eligible patients – supporting earlier intervention and expanding access to targeted therapy. "ZEGFROVY is a highly effective and currently the only approved EGFR TKI targeting EGFR exon 20 insertion mutations. The approval of ZEGFROVY will have a significant impact on platinum-pretreated patients with NSCLC harboring EGFR exon 20 insertion mutations, a difficult-to-treat lung cancer subtype," said Susan Chen, senior vice president, head of clinical operation at Dizal. "Today's FDA approval of the Oncomine Dx Express Test offers access to ZEGFROVY through decentralized companion diagnostic testing. The ability to match patients to our therapy quickly and accurately, regardless of mutation location, can improve outcomes for this patient population." To learn more about today's approval, please visit * Timing varies by number of samples and type of run. About Thermo Fisher ScientificThermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit View source version on Contacts Media Contact Information:Jen CarrollPhone: (760) 583-8898Email: Jessika ParryPhone: (419) 266-4016Email: jparry@
Yahoo
41 minutes ago
- Yahoo
ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data
New benchmark confirms LENSai's ability to accurately predict binding on 17 previously unseen antibody-antigen complexes, achieving near-crystallography precision without prior training data. AUSTIN, Texas, July 03, 2025--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), an AI-powered biotherapeutics company, today announced a new validation study supporting the generalizability of its proprietary epitope mapping platform, LENSai, powered by IPA's patented HYFT® technology. The newly released benchmark shows that the platform consistently delivers high predictive performance, even on complexes not used during training. "It's generally assumed that AI can only make accurate predictions if it has seen similar data before," said Dr. Jennifer Bath, CEO of ImmunoPrecise. "But this benchmark proves otherwise: LENSai accurately mapped antibody binding sites on entirely new antibody - protein complexes-none of which were used in training. Not the antibodies. Not the targets. Not the complexes. And the predictions aligned with wet-lab results. This is a major breakthrough in generalizing AI for therapeutic discovery, made possible by our proprietary technology, which captures functional meaning instead of memorizing shapes. It shows that AI doesn't always need massive data to be powerful and accurate - it just needs the right kind." LENSai Epitope Mapping uses artificial intelligence to pinpoint where antibodies are most likely to attach to disease-related proteins - helping scientists design better treatments faster. Unlike traditional methods that take months and require lab work, LENSai delivers results in hours - using just the digital sequences - cutting timelines, eliminating the need to produce expensive materials, reducing guesswork, and unlocking faster paths to new treatments. In a new benchmark study, LENSai was tested on 30 antibody-protein pairs, 17 of which the platform had never seen before. Despite having no prior exposure to these molecules, LENSai achieved prediction scores nearly identical to those from its original training data. This score, known as AUC (Area Under the Curve), is a widely accepted measure of accuracy in computational biology. The consistent performance on entirely new, unseen complexes confirms that LENSai's artificial intelligence can reliably analyze and predict antibody binding - even for molecules outside its training set. This breakthrough demonstrates LENSai's power to generalize across diverse biological structures, making it a valuable tool for accelerating real-world drug discovery. Why This Benchmark Matters In the new study, LENSai delivered high accuracy results on 17 antibody-protein complexes the platform had never seen before as it did on familiar training examples - proving true generalization, not memorization. Because no new wet-lab work or x-ray structures were required, researchers gain speed, reproducibility, and major cost savings, while freeing scarce lab resources for confirmatory or downstream assays. What It Means for Partners and Investors With LENSai already embedded in collaborations across big pharma and biotech, ImmunoPrecise is scaling access through secure APIs and custom partnerships. The platform helps researchers compress discovery timelines, reduce risk, and unlock previously unreachable targets - positioning the company and its investors at the forefront of AI-driven antibody therapeutics. For more technical detail and full benchmark results, explore two complementary case studies that illustrate the power and flexibility of LENSai Epitope Mapping. The first highlights performance on a "seen" target, where the system was trained on related data. The second - featured in this press release - demonstrates LENSai's breakthrough ability to accurately map binding sites on a completely "unseen" target, with no prior exposure to the antibody, the antigen, or their structure. New Case Study: LENSai Epitope Mapping on an "Unseen" Target [link] Previous Case Study: Head-to-Head Benchmark on a "Seen" Target [link] These examples underscore how LENSai performs both in well-characterized systems and in novel, previously untrained scenarios—validating its generalizability and real-world readiness. About ImmunoPrecise Antibodies Ltd. ImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT technology and LENSai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as "expects," "intends," "plans," "anticipates," "believes," or similar expressions, or by statements that certain actions, events, or results "may," "will," "could," or "might" occur or be achieved. These statements include, but are not limited to, statements regarding the performance, scalability, and broader application of the LENSai™ and HYFT® platforms; the generalizability of the Company's AI models to novel therapeutic targets; the role of AI in accelerating antibody discovery; and the Company's future scientific, commercial, and strategic developments. Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. These factors include, but are not limited to, the pace of scientific and technological innovation, risks related to model validation and generalizability in real-world settings, intellectual property protection, strategic partner adoption, regulatory pathways, and market demand for AI-driven therapeutic platforms. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at and EDGAR profile at Should any of these risks materialize, actual results could vary significantly from those currently anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances. View source version on Contacts Investor Relations Contact Louie TomaManaging Director, CORE IRinvestors@ Sign in to access your portfolio
